Ginkgo Bioworks Holdings Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

DNA$12.01-2.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands except share data)

	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	AccumulatedDeficit	AccumulatedOtherComprehensive(Loss) Income	Non-ControllingInterest	TotalStockholders’Equity
Balance as of December 31, 2021	40,284,804	$4	$3,805,001	$(2,297,925)	$(1,715)	$62,014	$1,567,379
Issuance of common stock upon exercise or vesting of equity awards	3,116,275	—	252	—	—	—	252
Tax withholdings related to net share settlement of equity awards	(7,390)	—	(981)	—	—	—	(981)
Issuance of common stock for business and asset acquisitions, net of issuance costs	2,862,931	—	279,745	—	—	—	279,745
Issuance of common stock pursuant to public offering, net of issuance costs	1,034,597	1	98,909	—	—	—	98,910
Issuance of common stock in exchange for services	8,182	—	1,000	—	—	—	1,000
Deconsolidation of subsidiaries	—	—	—	—	—	(55,408)	(55,408)
Acquisition of non-controlling interests	—	—	7,390	—	—	(7,390)	—
Adoption of ASC 842	—	—	—	5,195	—	—	5,195
Stock-based compensation expense	—	—	1,945,247	—	—	2,227	1,947,474
Foreign currency translation	—	—	—	—	(917)	—	(917)
Net loss	—	—	—	(2,104,929)	—	(1,443)	(2,106,372)
Balance as of December 31, 2022	47,299,399	5	6,136,563	(4,397,659)	(2,632)	—	1,736,277
Issuance of common stock upon exercise or vesting of equity awards	2,469,178	—	555	—	—	—	555
Tax withholdings related to net share settlement of equity awards	(360)	—	(23)	—	—	—	(23)
Settlement of contingent consideration	96,198	—	8,896	—	—	—	8,896
Issuance of common stock for asset acquisitions	119,278	—	6,820	—	—	—	6,820
Issuance of common stock in exchange for services	50,587	—	2,500	—	—	—	2,500
Forfeiture of restricted stock	(1,407)	—	—	—	—	—	—
Stock-based compensation expense and other	—	—	230,880	—	—	—	230,880
Foreign currency translation	—	—	—	—	4,116	—	4,116
Net loss	—	—	—	(892,869)	—	—	(892,869)
Balance as of December 31, 2023	50,032,873	5	6,386,191	(5,290,528)	1,484	—	1,097,152
Issuance of common stock upon exercise or vesting of equity awards	1,783,763	—	543	—	—	—	543
Payment for fractional shares after reverse stock split	—	—	(4)	—	—	—	(4)
Settlement of contingent consideration	1,385,532	—	14,742	—	—	—	14,742

Consolidated Statements of Stockholders’ Equity

(in thousands except share data)

	Common Stock
	Shares	Amount	AdditionalPaid-InCapital	AccumulatedDeficit	AccumulatedOtherComprehensive(Loss) Income	Non-ControllingInterest	TotalStockholders’Equity
Issuance of common stock for asset acquisitions	802,038	—	36,801	—	—	—	36,801
Issuance of common stock in exchange for services	361,579	—	4,799	—	—	—	4,799
Stock-based compensation expense	—	—	112,344	—	—	—	112,344
Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary	—	—	—	—	1,492	—	1,492
Foreign currency translation	—	—	—	—	(4,782)	—	(4,782)
Net loss	—	—	—	(547,029)	—	—	(547,029)
Balance as of December 31, 2024	54,365,785	$5	$6,555,416	$(5,837,557)	$(1,806)	$—	$716,058

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.